Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06229678 · ClinicalTrials.gov registry record · Early Phase 1

Ketones, SGLT2, HFrEF

A Early Phase 1 study of Heart Failure With Reduced Ejection Fraction and Type2diabetes, sponsored by The University of Texas Health Science Center at San Antonio.

Recruiting
Registry status
Early Phase 1
Development phase
71
Enrollment target
1
Study location

NCT06229678 is a Early Phase 1 study of Heart Failure With Reduced Ejection Fraction and Type2diabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 71 participants, below the 3,963-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06229678, a Early Phase 1 study of Heart Failure With Reduced Ejection Fraction and Type2diabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.

RECRUITING
Registry status
Early Phase 1
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great avidity by the myocardium, to measure change in Left Ventricle diastolic and systolic function

Conditions Studied

Heart Failure With Reduced Ejection Fraction Type2diabetes

Interventions

  • DRUG Placebo
  • DRUG Empagliflozin 25 MG Oral Tablet
  • DRUG Acipimox 250 Mg Oral Capsule

Study Locations (1)

Texas

  • Texas Diabetes Institute - University Health System - San Antonio

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2024-01-25
Est. Completion 2027-03-01
Phase Early Phase 1

Sponsor

The University of Texas Health Science Center at San Antonio

378 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06229678

The ClinicalTrials.gov registry entry for NCT06229678 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,963-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (98% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06229678 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06229678 about?

NCT06229678 is a clinical study titled "Ketones, SGLT2, HFrEF". The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great a...

What is the current status of trial NCT06229678?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 71 participants. The study started on 2024-01-25. Estimated completion is 2027-03-01.

What conditions does trial NCT06229678 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction, Type2diabetes.

What interventions are being tested in trial NCT06229678?

The interventions under investigation include: Placebo (DRUG), Empagliflozin 25 MG Oral Tablet (DRUG), Acipimox 250 Mg Oral Capsule (DRUG).

Who is sponsoring clinical trial NCT06229678?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06229678 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Reduced Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Reduced Ejection Fraction

All registered trials for this condition

Type2diabetes

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.